AADAC Polyclonal Antibody

• Background:

  Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens. Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide, which is an antiandrogen drug used for the treatment of prostate cancer that occasionally causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.

• Abbreviation:

  AADAC

• UniProt:

  P22760

• Host:

  Rabbit

• Reactivity:

  Human

• Immunogen:

  Recombinant protein of human AADAC

• Target:

  AAAD; Aada; Aadac; Arylacetamide deacetylase (esterase) ; Arylacetamide deacetylase; CES5A1; DAC

• Clonality:

  Polyclonal

• Conjugation:

  Unconjugated

• Applications:

  WB; IHC

• Field of Research:

  Metabolism; Signal Transduction

• Purification:

  Affinity purification

• Concentration:

  0.2 mg/mL

• Dilution:

  WB 1:500-1:2000; IHC 1:25-1:100

• Buffer:

  PBS with 0.05% sodium azide and 50% glycerol, PH7.4

• Shipping Conditions:

  The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended.

• Storage Conditions:

  Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.

• Calculated Molecular Weight:

  46kDa

• Isotype:

  IgG